Sury M R, Cole P V
Anaesthetics Laboratory, St Bartholomew's Hospital, West Smithfield, London.
Anaesthesia. 1988 Apr;43(4):281-4. doi: 10.1111/j.1365-2044.1988.tb08973.x.
Eighteen healthy volunteers were studied in a double-blind trial to determine which dose of nalbuphine (0.05, 0.1 or 0.2 mg/kg) may be combined with midazolam 0.05 mg/kg to provide a safe outpatient intravenous sedative technique. The ventilatory response to carbon dioxide and end tidal PCO2 were measured before and after the drugs were administered. A mild degree of respiratory depression occurred, which was maximal at 3-30 minutes after injection. This was not related to dose except that nalbuphine 0.05 mg/kg resulted in the slowest respiratory rates. The implications of these findings for clinical practice are discussed.
在一项双盲试验中对18名健康志愿者进行了研究，以确定哪种剂量的纳布啡（0.05、0.1或0.2毫克/千克）可与0.05毫克/千克的咪达唑仑联合使用，以提供一种安全的门诊静脉镇静技术。在给药前后测量了对二氧化碳的通气反应和呼气末二氧化碳分压。出现了轻度呼吸抑制，在注射后3至30分钟时最为明显。除了0.05毫克/千克的纳布啡导致呼吸频率最慢外，这种呼吸抑制与剂量无关。讨论了这些发现对临床实践的意义。
